Abivax reports excellent phase 2a clinical safety and efficacy results with 50mg ABX464 in rheumatoid arthritis

Written by Petra Hegmann on 23rd June 2021. Posted in Client News.

[image_slider_no_space on_click=”prettyphoto” height=”600″ navigation_style=”light” images=”940,950,954,952,953,951″]